Use of parenteral methotrexate significantly reduces the need for biological therapy [1]

Rheumatology

Volumn 47, Issue 2, 2008, Pages 222-

  Bharadwaj, Anurag ^a   Agrawal, S ^a   Batley, M ^a   Hammond, A ^a  

^a MAIDSTONE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FOLIC ACID; METHOTREXATE;

ADULT; AGED; BIOLOGICAL THERAPY; DISEASE DURATION; GASTROINTESTINAL TOXICITY; HUMAN; LETTER; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; REMISSION; RHEUMATOID ARTHRITIS; SCORING SYSTEM; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DISEASE PROGRESSION; HUMANS; METHOTREXATE; MIDDLE AGED; PATIENT SELECTION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 38649093636     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kem306     Document Type: Letter

References (7)

1. Ledingham J, Deighton C. On behalf of the British Society for Rheumatology Standards, Guidelines and Audit Working Group (SGAWG) Update on the British Society for Rheumatology guidelines for prescribing TNFα blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001). Rheumatology 2005;44:157-63
2. Deighton CM, George E, Kiely PDW, Ledingham J, Luqmani RA, Scott DGI. Updating the British Society for Rheumatology guidelines for anti-tumour necrosis factor therapy in adult rheumatoid arthritis (again). Rheumatology 2006;45:649-52.
3. Griffin AJ, Erkeller-Yuksel F. Parenteral methotrexate should be given before biological therapy. Rheumatology 2004;43:678.
4. Linda L, Hetland ML, Ostergaard M. Drug survival and reasons for discontinuation of intramuscular methotrexate: A study of 212 consecutive patients switching from oral mathotrexate. Scand J Rheumatol 2006;35:102-6.
5. Wegrzyn J, Adeleine P, Miossec P., Better efficacy of methotrexate given by intramuscular injection than orally in patients with rheumatoid arthritis. Ann Rheum Dis 2004;63:1232-4.
6. Hamilton RA, Kremer JM. Why intramuscular methotrexate may be more efficacious than-oral dosing in patients wfth rheumatoid arthritis. Br J Rheumatol 1997;36:86-90.
7. Hoekstra M, Haagsma C, Neef C, Proost J et al. Bioavailability of higher dose mathotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis. J Rheumatol 2004;31:645-8.